Centanafadine hydrochloride
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Centanafadine hydrochloride
- Molecular weight
- 245.75
- Structure (SMILES)
- Cl.c1ccc2cc([C@]34CNC[C@H]3C4)ccc2c1
- centanafadine hydrochloride
- Centanafadine hydrochloride
- CENTANAFADINE HYDROCHLORIDE [USAN]
- Centanafadine hydrochloride [WHO-DD]
- centanafadine hydrochloride usan
- centanafadine hydrochloride who dd
- CENTANAFADINE HYDROCHLORIDE, (+)-
- dov 216 419
- dov 216 419 hydrochloride
- DOV 216,419
- DOV 216,419 HYDROCHLORIDE
- dov 216419 hydrochloride
- DOV-216419 HYDROCHLORIDE
- eb 1020
- eb 1020 hydrochloride
- EB-1020
- EB-1020 HYDROCHLORIDE
- simtriyo
- SIMTRIYO
- CAS registry numbers
- 923981-14-0
- ChEMBL ID
- CHEMBL3301615
- InChIKey
- ACVMJAJGCQUPKX-LIOBNPLQSA-N
- PubChem compound IDs
- 68943792
- FDA ingredient codes (UNII)
- 265DN9X85W
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -fadine
Open Targets mechanisms
- Mechanism
- Monoamine transporter inhibitor
- Action type
- Inhibitor
- Target
- Monoamine transporter
Investigated indications
- Condition
- Attention Deficit Disorder with Hyperactivity
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003888
- Subject identifier
- D001289
- Condition identifier
- EFO_0003888
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002009
- Condition identifier
- MONDO_0002009
- Highest recorded phase
- 0
- Condition identifier
- MONDO_0007743
- Highest recorded phase
- 3
- NCT05257265
- NCT05279313
- Hydrogen bond acceptors
- 1
- Hydrogen bond donors
- 1
- Polar surface area
- 12.03
- Calculated partition coefficient (ALogP)
- 2.7
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 1
- Heavy atoms
- 17
- Molecular formula
- C15H16ClN
- Monoisotopic mass
- 245.0971272
- Natural product
- No
Related records
Trials (23)
- A Long-term Trial of EB-1020 in Adult Patients With ADHD
- A Long-term Trial of EB-1020 in Pediatric Patients With ADHD
- A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users
- A Study to Evaluate the Safety, Tolerance, and Pharmacokinetic and Pharmacodynamic Profile Of 1 SR Formulation of EB-1020
- A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation
- A Trial Evaluating the Efficacy, Safety, & Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder
- A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder
- A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention- Deficit/Hyperactivity Disorder
- A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)
- A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating Disorder
- A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.
- A Trial to Assess How Centanafadine Interacts With Stimulants in the Body
- A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder
- A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine in Pediatric Subjects With Attention-deficit/Hyperactivity Disorder
- A Trial to Compare the Amount of Centanafadine That Enters the Bloodstream for Two Different Formulations of Centanafadine
- A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD
- A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder
- Efficacy of Centanafadine SR as a Potential Smoking Cessation Treatment
- Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients
- Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD)
In development for (1)
- Attention deficit-hyperactivity disorder Phase 3